Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biological Standardization of Ambrosia elatior Allergen Extract
2011-002096-42Phase 2Completed
- Sponsor
- LETI Pharma
- Start
- May 2012
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ambrosia elatior allergen extract in ragweed allergy, sponsored by LETI Pharma. Primary endpoint: Immediate wheal size area to Ambrosia elatior extract. Started May 2012; status: completed.
02
Drugs
ambrosia elatior allergen extract
03
Conditions
ragweed allergy
Beyond the preview
Go deeper on 2011-002096-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-002096-42.